Safety and Efficacy Study of GEB-101 Injection in Subjects With TGFBI-related Corneal Dystrophy

The goal of this clinical trial is to evaluate the safety and efficacy of GEB-101 injection in subjects with TGFBI-related Corneal Dystrophy

Inclusion Criteria: * Males or females, age 18-70 years (inclusive). * TGFBI gene mutation confirmed. * Patients with corneal dystrophy who are symptomatic. * Willing and able to give signed informed consent and follow study instructions. Exclusion Criteria: * In either eye: Have any active infection, glaucoma, corneal disease, or other ocular conditions that may affect the assessment of efficacy or safety. * In the study eye: Have a history of specific intraocular or corneal surgery, or the presence of active intraocular inflammation or vitreous hemorrhage. * Patient with other corneal disorders that may hinder therapeutic surgery or interfere with the interpretation of study results. * Prior gene therapy administration in either eye. * Active infection occurring or suspected within 4 weeks prior to the investigational product, requiring systemic anti-infective therapy. * Subjects with a history of major cardiovascular events within 6 months, the presence of any clinically significant condition, a diagnosis of malignancy within 5 years (with specified exceptions), or active infection with HIV, syphilis, hepatitis C, or hepatitis B. * Female subjects who are pregnant, breastfeeding, or planning to become pregnant during the study period. * Disease, condition, or disorder that in the judgement of Investigator could confound study assessments or limit compliance to study protocol.